Atopic Dermatitis
Safety and immunogenicity of modified vaccinia Ankara as a smallpox vaccine in people with atopic dermatitis
Vaccine, 32, 5696-702Long-term safety of replication-defective smallpox vaccine (MVA-BN) in atopic eczema and allergic rhinitis
J Eur Acad Dermatol Venereol, 30, 1971-1977A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis
PLoS One, 10, e0138348